Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : $89.0 million
Deal Type : Series D Financing
Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-Focused Pipeline
Details : The proceeds from the financing will be used to further advance the ongoing clinical development of Agomab’s lead candidate, AGMB-129 in patients with fibrostenosing Crohn’s disease (FSCD).
Product Name : AGMB-129
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 25, 2024
Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : $89.0 million
Deal Type : Series D Financing
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : ABO Securities
Deal Size : Undisclosed
Deal Type : Financing
BioSenic Signs a New Subscription Agreement for a Maximum of EUR 1.2M in Convertible Bonds
Details : The proceeds from the financing will contribute to advancing clinical development of BioSenic’s lead asset its ATO product, Arscimed (arsenic trioxide), for treating chronic graft versus host disease.
Product Name : Arscimed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
August 01, 2024
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : ABO Securities
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioSenic Releases New Analysis of Phase 2 Data for Arsenic Trioxide in cGvHD
Details : Arscimed (arsenic trioxide) is a thioredoxin reductase 1 inhibitor small molecule drug candidate, which is being evaluated for the treatment of chronic graft versus host disease.
Product Name : Arscimed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
July 18, 2024
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : ABO Securities
Deal Size : $2.2 million
Deal Type : Agreement
BioSenic Signs a New Subscription Agreement for a Maximum of EUR 2.1M in Convertible Bonds
Details : The proceeds of the financing will essentially contribute to continuing to advance the clinical development of Arscimed (arsenic trioxide) in the treatment of chronic graft versus host disease.
Product Name : Arscimed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
June 21, 2024
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : ABO Securities
Deal Size : $2.2 million
Deal Type : Agreement
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Phebra
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Medsenic Subsidiary Signs Licensing Agreement with Phebra PTY Ltd
Details : Medsenic and Phebra should facilitate the final steps of manufacturing, clinical confirmation of efficacy and subsequent commercialization of oral ArsciCor (arsenic trioxide) in cGvHD.
Product Name : Arscimed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
February 07, 2024
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Phebra
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATO (arsenic trioxide) is administered daily by IV infusions, which is investigated for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious disease.
Product Name : Arscimed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 27, 2023
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GLPG3667
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor and currently in development for the treatment of inflammatory and auto-immune diseases such as systemic lupus erythematosus.
Product Name : GLPG3667
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2023
Lead Product(s) : GLPG3667
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GLPG3667
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor and currently in development for the treatment of inflammatory and auto-immune diseases such as dermatomyositis.
Product Name : GLPG3667
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : GLPG3667
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AGMB-129 (ORG-129) is an oral, small molecule GI-restricted inhibitor of ALK-5 (or TGFbR1) for the treatment of Fibrostenosing Crohn’s Disease. TGFb is a known master regulator of fibrosis and preliminary clinical data supports targeting the pathway in...
Product Name : AGMB-129
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2023
Lead Product(s) : AGMB-129
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arsenic Trioxide,Metal ion
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arscimed® (arsenic trioxide), is a able to radically modify the autoimmune cascade and normalise the immune system without causing nonspecific immunosuppressionbeing studied for cGvHD.
Product Name : Arscimed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : Arsenic Trioxide,Metal ion
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable